Wegovy 2.4mg Not Working? Could 7.2mg Be the Next Step?

You've reached Wegovy 2.4 mg, you're taking it consistently, but your weight has stopped moving.

So has Wegovy stopped working?

Not necessarily.

Weight loss is rarely linear, and reaching a plateau does not automatically mean that semaglutide has stopped having an effect.

But there is now another option that did not exist when Wegovy first launched in the UK: Wegovy 7.2 mg.

What is Wegovy 7.2mg?

The MHRA has authorised a maximum Wegovy dose of 7.2 mg once weekly for weight management in adults with obesity where clinically needed.

Patients must first reach and remain on the standard 2.4 mg weekly maintenance dose for at least four weeks before 7.2 mg can be considered.

It isn't a dose everyone should automatically progress to.

Does 7.2mg produce more weight loss?

The STEP UP trial compared once-weekly semaglutide 7.2 mg with 2.4 mg and placebo in adults with obesity.

When analysing participants regardless of whether they remained on treatment exactly as planned, average weight reduction at 72 weeks was:

18.7% with 7.2 mg
15.6% with 2.4 mg
3.9% with placebo

More people receiving 7.2 mg also achieved weight reductions of 20% and 25% or more.

That does not mean everybody on 2.4 mg should increase.

Before blaming the dose, review the plateau

Your clinician may consider:

how long your weight has actually been stable
how much weight you have already lost
whether appetite suppression is still present
diet and protein intake
activity levels
side effects,
other medication
whether further weight loss is clinically appropriate.

A couple of weeks without movement is not necessarily a true plateau.

Is 7.2mg suitable if my BMI is already below 30?

This needs individual clinical assessment but maybe.

The higher 7.2 mg dose is specifically authorised for weight management in adults with obesity, and your prescriber needs to consider your current treatment stage, weight trajectory, overall health and treatment goals before increasing treatment.

What about side effects?

Higher treatment intensity can also mean greater tolerability issues.

Gastrointestinal adverse effects such as nausea, vomiting, diarrhoea and constipation remain important with semaglutide, and the STEP UP programme found gastrointestinal events were more frequent with 7.2 mg than with 2.4 mg.

How Pharmulous can help

At Pharmulous, we don't believe that reaching a higher dose should automatically mean moving to it.

If you're established on Wegovy 2.4 mg but your progress has changed, our clinicians can review your weight trajectory, appetite control, tolerability and longer-term goals before deciding whether remaining on 2.4 mg, changing your treatment strategy or considering 7.2 mg is appropriate.

The goal isn't the highest dose. It's the dose and treatment plan that works safely for you.